NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 313 filers reported holding NOVOCURE LTD in Q4 2022. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,090,577 | -70.7% | 439,045 | -24.7% | 0.00% | -80.0% |
| Q2 2023 | $24,196,037 | -34.8% | 583,037 | -5.6% | 0.01% | -28.6% |
| Q1 2023 | $37,131,519 | -16.1% | 617,418 | +2.4% | 0.01% | -22.2% |
| Q4 2022 | $44,236,578 | -3.0% | 603,089 | +0.5% | 0.01% | -10.0% |
| Q3 2022 | $45,588,000 | +5.7% | 600,008 | -3.3% | 0.01% | +11.1% |
| Q2 2022 | $43,133,000 | -18.3% | 620,611 | -2.6% | 0.01% | 0.0% |
| Q1 2022 | $52,795,000 | +10.9% | 637,237 | +0.5% | 0.01% | +12.5% |
| Q4 2021 | $47,618,000 | -35.4% | 634,231 | -0.1% | 0.01% | -38.5% |
| Q3 2021 | $73,755,000 | -43.1% | 634,891 | +8.6% | 0.01% | -43.5% |
| Q2 2021 | $129,721,000 | +73.6% | 584,804 | +3.5% | 0.02% | +64.3% |
| Q1 2021 | $74,718,000 | -23.5% | 565,280 | +0.2% | 0.01% | -26.3% |
| Q4 2020 | $97,655,000 | +90.1% | 564,348 | +22.3% | 0.02% | +72.7% |
| Q3 2020 | $51,379,000 | +190.2% | 461,588 | +54.6% | 0.01% | +175.0% |
| Q2 2020 | $17,706,000 | -72.3% | 298,578 | -68.5% | 0.00% | -77.8% |
| Q1 2020 | $63,915,000 | -23.2% | 949,122 | -3.9% | 0.02% | -5.3% |
| Q4 2019 | $83,223,000 | +8.8% | 987,578 | -3.4% | 0.02% | +5.6% |
| Q3 2019 | $76,472,000 | +36.7% | 1,022,633 | +15.6% | 0.02% | +38.5% |
| Q2 2019 | $55,923,000 | +46.7% | 884,456 | +11.8% | 0.01% | +44.4% |
| Q1 2019 | $38,119,000 | +45.9% | 791,328 | +1.4% | 0.01% | +28.6% |
| Q4 2018 | $26,123,000 | -38.0% | 780,230 | -3.0% | 0.01% | -30.0% |
| Q3 2018 | $42,155,000 | +77.9% | 804,471 | +6.3% | 0.01% | +66.7% |
| Q2 2018 | $23,693,000 | +95.1% | 756,959 | +35.9% | 0.01% | +100.0% |
| Q1 2018 | $12,142,000 | +7.3% | 556,961 | -0.5% | 0.00% | 0.0% |
| Q4 2017 | $11,311,000 | -1.6% | 559,936 | -3.3% | 0.00% | 0.0% |
| Q3 2017 | $11,490,000 | +13.0% | 578,871 | -1.5% | 0.00% | 0.0% |
| Q2 2017 | $10,167,000 | +146.3% | 587,698 | +15.3% | 0.00% | +200.0% |
| Q1 2017 | $4,128,000 | +10.1% | 509,651 | +6.7% | 0.00% | 0.0% |
| Q4 2016 | $3,751,000 | -5.9% | 477,754 | +2.4% | 0.00% | 0.0% |
| Q3 2016 | $3,985,000 | -28.8% | 466,612 | -2.7% | 0.00% | -50.0% |
| Q2 2016 | $5,598,000 | +417.4% | 479,666 | +542.1% | 0.00% | – |
| Q1 2016 | $1,082,000 | -35.0% | 74,705 | +0.3% | 0.00% | -100.0% |
| Q4 2015 | $1,665,000 | – | 74,446 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |